H7 ANGEL SYNDICATE
H7 angel syndicate invests through SPVs to back high-potential life science and medtech companies from seed to pre-IPO. We bring together experienced investors to participate in curated, deal-specific opportunities that accelerate breakthrough innovations toward clinical and commercial success.
OUR MEMBERS
Our syndicate consists of individual investors who choose which deals they want to join. Each member evaluates opportunities independently and invests based on their own judgment.
Our membership includes a diverse group of healthcare-focused investors and industry enthusiasts. In addition to angel investors, family offices, and venture capital professionals, we also bring together corporate executives, physicians, scientists, engineers, and entrepreneurs—bringing deep expertise across the life sciences and medtech ecosystem.
INVESTMENT PROCESS
The H7 investment team brings forward opportunities only after completing rigorous due diligence and preparing a comprehensive investment memo. Each deal is structured through a single entity (SPV), allowing members to participate with smaller checks (minimum $50,000). This structure helps investors diversify their exposure while accessing high-quality, carefully vetted opportunities.
INVESTMENT FOCUS
We are deeply immersed in the therapeutic and medtech sectors, focusing on high-quality opportunities from seed to pre-IPO. Our investment emphasis is on therapeutic companies in IND-enabling or clinical development, as well as medtech companies that are post-revenue or supported by strong clinical validation.
